Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 TrialMarco Beldinanzi, Sabina Chiaretti, Daniele Mattei et al.|Blood|2024Cited by 0